Christopher Ryan Sullivan - 15 May 2023 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Role
Chief Financial Officer
Signature
/s/ Jennifer Zoltoski, by Power of Attorney
Issuer symbol
AVTX
Transactions as of
15 May 2023
Net transactions value
$0
Form type
4
Filing time
17 May 2023, 07:44:53 UTC
Previous filing
15 Feb 2023
Next filing
13 Jun 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTX Stock Option (Right to Buy) Award $0 +40,000 $0.000000 40,000 15 May 2023 Common Stock 40,000 $2.75 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option will vest in full on May 15, 2024, subject to the Reporting Person's continued service on such vesting date.